List view / Grid view
13 July 2015 | By Oxford Global
With four months to go until the Next Generation Sequencing USA Congress and co-located Single Cell Genomics and Transcriptomics USA Congress, Oxford Global Conferences are delighted to announce the release of the final agenda...
Find out about the science behind Affimers - including why Affimers are superior to antibodies and details about our custom Affimer process...
Find out more about the applications of Affimers, including how Affimers can be used in the development of therapeutics...
This video introduces Avacta Life Sciences, part of Avacta Group plc and its flagship product, Affimers - a revolutionary new, engineered alternative to antibodies...
26 May 2015 | By Oxford Global Conferences
In the run up to the Next Generation Sequencing USA Congress & co-located Single Cell Genomics and Transcriptomics USA Congress, Oxford Global Conferences interviewed Ben Busby, Genomics Outreach Coordinator, NCBI...
Medicine and life sciences research are being revolutionised by major technological developments that have taken place over the past decade. High-throughput sequencers can now generate high-quality nucleotide sequence data at a small fraction of the cost compared to only a few years back...
9 April 2015 | By Caroline Richards, Editor, Drug Target Review
In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
10 March 2015 | By TATAA Biocenter and Qlucore
TATAA Biocenter, the world's premier organizer of hands-on training in molecular diagnostics and Europe´s leading provider of genomic services, has announced a partnership with Qlucore for the analyses of Next Generation Sequencing (NGS) data...
DNA sequencing technologies have come on leaps and bounds since the double-helical structure of DNA was first discovered in 1953 by genetics pioneers James Watson and Francis Crick. This discovery paved the way to the development, years later, of next generation sequencing (NGS), a high-throughput technology that enables scientists to…
27 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc., a privately held company, based in Mountain View, California, USA...
In November 2013, the US Food and Drug Administration (FDA) allowed for the first time the marketing of high-throughput DNA sequencing technology for diagnostic testing. It was a breakthrough year for Next Generation Sequencing (NGS)...
